OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)

被引：3
作者：
Robson, Mark E. [1 ]
Im, Seock-Ah [2 ]
Senkus, Elzbieta [3 ]
Xu, Binghe [4 ]
Domchek, Susan [5 ]
Masuda, Norikazu [6 ]
Delaloge, Suzette [7 ]
Li, Wei [8 ]
Tung, Nadine [9 ]
Armstrong, Anne [10 ]
Wu, Wenting [11 ]
Goessl, Carsten [11 ]
Runswick, Sarah [12 ]
Conte, Pierfranco [13 ,14 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Med Univ Gdansk, Gdansk, Poland
[4] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[5] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA
[6] Natl Hosp Org, Osaka Natl Hosp, Osaka, Japan
[7] Inst Gustave Roussy, Villejuif, France
[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[9] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[11] AstraZeneca, Gaithersburg, MD USA
[12] AstraZeneca, Macclesfield, Cheshire, England
[13] Univ Padua, Padua, Italy
[14] Ist Oncol Veneto IRCCS, Padua, Italy
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT038
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical outcomes, treatment patterns and health resource utilization (HRU) among metastatic breast cancer (mbc) patients (pts) with germline BRCA mutation (gBRCAm)
    Quek, R.
    Mardekian, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [32] Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
    Kuemmel, Sherko
    Jackisch, Christian
    Mueller, Volkmar
    Schneeweiss, Andreas
    Klawitter, Sandra
    Lux, Michael P.
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 5423 - 5431
  • [33] OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
    Robson, Mark
    Tutt, Andrew
    Balmana, Judith
    Kaufman, Bella
    Garber, Judy
    Geyer, Charles
    Ford, James
    Sharma, Priyanka
    Stuart, Mary
    Mann, Helen
    Fasching, Peter A.
    [J]. CANCER RESEARCH, 2015, 75
  • [34] Germline BRCA1 and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry.
    Fasching, Peter A.
    Hu, Chunling
    Hart, Steven
    Hartkopf, Andreas D.
    Taran, Florin A.
    Janni, Wolfgang
    Tesch, Hans
    Haeberle, Lothar
    Ettl, Johannes
    Overkamp, Friedrich
    Lux, Michael P.
    Luftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Kolberg, Hans-Christian
    Fehm, Tanja N.
    Wallwiener, Diethelm
    Brucker, Sara
    Schneeweiss, Andreas
    Couch, Fergus
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Cost-effectiveness analysis of eribulin (E) versus treatment of physician's choice (TPC) in patients (pts) with pretreated metastatic breast cancer (MBC).
    Montero, Alberto J.
    Avancha, Kiran Kumar Venkata Raja
    Gluck, Stefan
    Lopes, Gilberto de Lima
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation
    Gelmon, Karen
    Walker, Graham P.
    Fisher, Graham V.
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [37] Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer
    Tuffaha, Haitham
    Scuffham, Paul
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 64 - 65
  • [38] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
    Xu, Binghe
    Sun, Tao
    Shi, Yanxia
    Cui, Jiuwei
    Yin, Yongmei
    Ouyang, Quchang
    Liu, Qiang
    Zhang, Qingyuan
    Chen, Yiding
    Wang, Shouman
    Wang, Xiaojia
    Tong, Zhongsheng
    Zhong, Yahua
    Wang, Jiayu
    Yan, Min
    Yan, Xi
    Wang, Chuan
    Feng, Jifeng
    Wang, Xiuli
    Hu, Gang
    Cheng, Ying
    Ge, Ruimin
    Zhu, Zhaoyin
    Zhang, Wa
    Shao, Zhimin
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2022, 197 (3) : 489 - 501
  • [39] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
    Binghe Xu
    Tao Sun
    Yanxia Shi
    Jiuwei Cui
    Yongmei Yin
    Quchang Ouyang
    Qiang Liu
    Qingyuan Zhang
    Yiding Chen
    Shouman Wang
    Xiaojia Wang
    Zhongsheng Tong
    Yahua Zhong
    Jiayu Wang
    Min Yan
    Xi Yan
    Chuan Wang
    Jifeng Feng
    Xiuli Wang
    Gang Hu
    Ying Cheng
    Ruimin Ge
    Zhaoyin Zhu
    Wa Zhang
    Zhimin Shao
    [J]. Breast Cancer Research and Treatment, 2023, 197 : 489 - 501
  • [40] Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation
    Frenel, J. -S.
    Lusque, A.
    Delaloge, S.
    Ferrero, J. -M.
    Bachelot, T.
    Desmoulins, I.
    Levy, C.
    Eymard, J. -C.
    Goncalves, A.
    Patsouris, A.
    Reynier, M. A. Mouret
    Thery, M. J. -C.
    Petit, T.
    Cabel, L.
    Uwer, L.
    Debled, M.
    Chevrot, M.
    Mailliez, A.
    Jacot, W.
    Rouge, T. de la Motte
    [J]. BRITISH JOURNAL OF CANCER, 2023, 128 (11) : 2072 - 2080
12345